← Back to Search
Functionalized Superparamagnetic Iron Oxide Nanoparticles (SPIONs) As Platform For The Targeted Multimodal Tumor Therapy
C. Janko, Teresa Ratschker, K. Nguyen, Lisa Zschiesche, R. Tietze, S. Lyer, C. Alexiou
Published 2019 · Medicine
Download PDFAnalyze on Scholarcy
Standard cancer treatments involve surgery, radiotherapy, chemotherapy, and immunotherapy. In clinical practice, the respective drugs are applied orally or intravenously leading to their systemic circulation in the whole organism. For chemotherapeutics or immune modulatory agents, severe side effects such as immune depression or autoimmunity can occur. At the same time the intratumoral drug doses are often too low for effective cancer therapy. Since monotherapies frequently cannot cure cancer, due to their synergistic effects multimodal therapy concepts are applied to enhance treatment efficacy. The targeted delivery of drugs to the tumor by employment of functionalized nanoparticles might be a promising solution to overcome these challenges. For multimodal therapy concepts and individualized patient care nanoparticle platforms can be functionalized with compounds from various therapeutic classes (e.g. radiosensitizers, phototoxic drugs, chemotherapeutics, immune modulators). Superparamagnetic iron oxide nanoparticles (SPIONs) as drug transporters can add further functionalities, such as guidance or heating by external magnetic fields (Magnetic Drug Targeting or Magnetic Hyperthermia), and imaging-controlled therapy (Magnetic Resonance Imaging).
This paper references
Brain tumor targeting of magnetic nanoparticles for potential drug delivery: effect of administration route and magnetic field topography.
B. Chertok (2011)
The oxygen effect in radiation inactivation of DNA and enzymes.
M. Quintiliani (1986)
Nanoparticle distribution during systemic inflammation is size-dependent and organ-specific.
K. Chen (2015)
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
R. Schreiber (2011)
Targeted nanoparticle delivery of therapeutic antisense microRNAs presensitizes glioblastoma cells to lower effective doses of temozolomide in vitro and in a mouse model
M. Malhotra (2018)
A molecular and preclinical comparison of the PD-1–targeted T-cell checkpoint inhibitors nivolumab and pembrolizumab
Petros Fessas (2017)
Treating with Checkpoint Inhibitors-Figure $1 Million per Patient.
Audrey Andrews (2015)
lessons for immuno-oncology
Sengupta S. Cancer nanomedicine (2017)
Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date
Daniel Bobo (2016)
Understanding and overcoming major barriers in cancer
S Nie (2010)
State-of-the-art in design rules for drug delivery platforms: lessons learned from FDA-approved nanomedicines.
Charlene M. Dawidczyk (2014)
Role of functionalization: strategies to explore potential nano-bio applications of magnetic nanoparticles
R. Bohara (2016)
Consensus guidelines for the detection of immunogenic cell death
O. Kepp (2014)
Different Storage Conditions Influence Biocompatibility and Physicochemical Properties of Iron Oxide Nanoparticles
Jan Zaloga (2015)
J. Crawford (2004)
Tumor-Specific Antigens and Immunologic Adjuvants in Cancer Immunotherapy
Teofila Seremet (2011)
Inducers of immunogenic cancer cell death.
A. Dudek (2013)
The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect.
J. Fang (2011)
Immunogenic cell death in cancer therapy.
G. Kroemer (2013)
a biocompatible, size-tunable contrast agent for magnetic resonance imaging
H Unterweger (2017)
Radiation therapy to convert the tumor into an in situ vaccine.
S. Formenti (2012)
Risk factors of treatment-related death in chemotherapy and thoracic radiotherapy for lung cancer.
Y. Ohe (2001)
Checkpoint inhibitors: outstanding efficacy but at what cost?
J. Klastersky (2016)
Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation
G. Freeman (2000)
Epoetin Biosimilars in the Treatment of Chemotherapy-Induced Anemia: 10 Years’ Experience Gained
M. Aapro (2018)
Chemotherapy interruptions in relation to symptom severity in advanced breast cancer
Gwen Wyatt (2015)
T cell-targeting nanoparticles focus delivery of immunotherapy to improve antitumor immunity
D. Schmid (2017)
Non-immunogenic dextran-coated superparamagnetic iron oxide nanoparticles: a biocompatible, size-tunable contrast agent for magnetic resonance imaging
H. Unterweger (2017)
Near-infrared emitting fluorophore-doped calcium phosphate nanoparticles for in vivo imaging of human breast cancer.
E. Altınoğlu (2008)
tolerance and efficacy
AS Lubbe (1996)
the phagocyte problem
HH Gustafson (2015)
Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis.
L. Kwak (1990)
Enhancement of Antitumor Immunity by CTLA-4 Blockade
D. Leach (1996)
Superparamagnetic iron oxide nanoparticles as radiosensitizer via enhanced reactive oxygen species formation.
S. Klein (2012)
Nivolumab as first line monotherapy for advanced non-small cell lung cancer: could we replace first line chemotherapy with immunotherapy?
H. West (2014)
Nanoparticle delivery of siRNA against TWIST to reduce drug resistance and tumor growth in ovarian cancer models.
Cai M. Roberts (2017)
Nanoparticle Uptake: The Phagocyte Problem.
Heather Herd Gustafson (2015)
Macrophage Endocytosis of Superparamagnetic Iron Oxide Nanoparticles: Mechanisms and Comparison of Ferumoxides and Ferumoxtran-10
I. Raynal (2004)
Magnetically-enabled and MR-monitored selective brain tumor protein delivery in rats via magnetic nanocarriers.
B. Chertok (2011)
Development of a lauric acid/albumin hybrid iron oxide nanoparticle system with improved biocompatibility
J. Zaloga (2014)
Superparamagnetic iron oxide nanoparticles as novel X-ray enhancer for lowdose radiation therapy
S Klein (2014)
Efficient tumor targeting of hydroxycamptothecin loaded PEGylated niosomes modified with transferrin.
Minghuang Hong (2009)
Immune Profiling of Cancer Patients Treated with Immunotherapy: Advances and Challenges
L. Pilla (2018)
Neoantigens in cancer immunotherapy
T. Schumacher (2015)
Magnetite nanoparticles for cancer diagnosis, treatment, and treatment monitoring: recent advances.
R. Revia (2016)
Comprehensive cytotoxicity studies of superparamagnetic iron oxide nanoparticles
R. Patil (2018)
Current Challenges in Cancer Treatment.
J. Zugazagoitia (2016)
Mutation selection and the natural history of cancer
J. Cairns (1975)
Tumor microenvironmental physiology and its implications for radiation oncology.
P. Vaupel (2004)
Oral Nanoparticles Exhibit Specific High-Efficiency Intestinal Uptake and Lymphatic Transport.
K. Kim (2018)
Inert Coats of Magnetic Nanoparticles Prevent Formation of Occlusive Intravascular Co-aggregates With Neutrophil Extracellular Traps
R. Bilyy (2018)
Clearance properties of nano-sized particles and molecules as imaging agents: considerations and caveats.
M. Longmire (2008)
Doxorubicin-modified magnetic nanoparticles as a drug delivery system for magnetic resonance imaging-monitoring magnet-enhancing tumor chemotherapy
Po-Chin Liang (2016)
Targeted drug delivery to tumors: myths, reality and possibility.
Y. Bae (2011)
Nanoparticle-based immunotherapy for cancer.
Kun Shao (2015)
Economic sustainability of anti-PD-1 agents nivolumab and pembrolizumab in cancer patients: Recent insights and future challenges.
F. Tartari (2016)
10 years’ experience gained
M Aapro (2018)
selection of suitable superparamagnetic iron oxide nanoparticles
M Mühlberger (2019)
challenges and future trends
Ventola CL. Cancer immunotherapy (2017)
Radionuclides delivery systems for nuclear imaging and radiotherapy of cancer.
M. Hamoudeh (2008)
G. Chen (1939)
considerations and caveats
M Longmire (2008)
Superparamagnetic iron oxide nanoparticles as novel X-ray enhancer for low-dose radiation therapy.
S. Klein (2014)
Cancer and the Immune System: Basic Concepts and Targets for Intervention.
D. Pardoll (2015)
Irradiation of Tumor Cells Up-Regulates Fas and Enhances CTL Lytic Activity and CTL Adoptive Immunotherapy
M. Chakraborty (2003)
Lethality in mammalian cells due to hyperthermia under oxic and hypoxic conditions.
H. Bass (1978)
Side effects of adjuvant treatment of breast cancer.
C. Shapiro (2001)
Cancer active targeting by nanoparticles: a comprehensive review of literature
Remon Bazak (2014)
Strategies to optimize the biocompatibility of iron oxide nanoparticles – “SPIONs safe by design”
C. Janko (2017)
Doxorubicin loaded magnetic gold nanoparticles for in vivo targeted drug delivery.
N. Elbialy (2015)
Potential toxicity of superparamagnetic iron oxide nanoparticles (SPION)
N. Singh (2010)
Immunoengineering: How Nanotechnology Can Enhance Cancer Immunotherapy
M. Goldberg (2015)
Improving DNA double-strand repair inhibitor KU55933 therapeutic index in cancer radiotherapy using nanoparticle drug delivery.
Xi Tian (2015)
Antibody-conjugated gold-gold sulfide nanoparticles as multifunctional agents for imaging and therapy of breast cancer
E. Day (2010)
Cancer Immunotherapy, Part 3: Challenges and Future Trends.
C. Ventola (2017)
Dextran-coated superparamagnetic iron oxide nanoparticles for magnetic resonance imaging: evaluation of size-dependent imaging properties, storage stability and safety
H. Unterweger (2018)
Detection of breast cancer cells using targeted magnetic nanoparticles and ultra-sensitive magnetic field sensors
H. Hathaway (2011)
Faculty Opinions recommendation of Cancer immunotherapy: harnessing the immune system to battle cancer.
G. Vecchio (2019)
the future of biocompatible magnetism
RA Meyer (2015)
Nanotechnology for Multimodal Synergistic Cancer Therapy.
W. Fan (2017)
Recent insights and future challenges
F Tartari (2016)
pH-Responsive Magnetic Mesoporous Silica-Based Nanoplatform for Synergistic Photodynamic Therapy/Chemotherapy.
Xiang-long Tang (2018)
New Immunotherapies in Oncology Treatment and Their Side Effect Profiles
Pramern Sriratana (2018)
Pharmaceutical formulation of HSA hybrid coated iron oxide nanoparticles for magnetic drug targeting.
J. Zaloga (2016)
HPMA copolymer-bound doxorubicin induces immunogenic tumor cell death.
M. Šírová (2013)
Understanding and overcoming major barriers in cancer nanomedicine.
Shuming Nie (2010)
Doxorubicin-Hyaluronan Conjugated Super-Paramagnetic Iron Oxide Nanoparticles (DOX-HA-SPION) Enhanced Cytoplasmic Uptake of Doxorubicin and Modulated Apoptosis, IL-6 Release and NF-kappaB Activity in Human MDA-MB-231 Breast Cancer Cells.
D. Vyas (2015)
myths, reality and possibility
YH Bae (2011)
Renal clearance of quantum dots
H. Choi (2007)
Tumor selectivity of stealth multi-functionalized superparamagnetic iron oxide nanoparticles.
Caixia Fan (2011)
Preclinical experiences with magnetic drug targeting: tolerance and efficacy.
A. Lübbe (1996)
Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy.
P. Aggarwal (2009)
Mechanisms of multidrug resistance in cancer.
J. Gillet (2010)
Functionalization of T lymphocytes for magnetically controlled immune therapy: Selection of suitable superparamagnetic iron oxide nanoparticles
Marina Mühlberger (2019)
Antibodyconjugated gold-gold sulfide nanoparticles as multifunctional agents for imaging and therapy of breast cancer
ES Day (2010)
a comprehensive review of literature
R Bazak (2015)
Effect of ultrasmall superparamagnetic iron oxide nanoparticles (Ferumoxtran-10) on human monocyte-macrophages in vitro.
K. Mueller (2007)
Nano-enabled pancreas cancer immunotherapy using immunogenic cell death and reversing immunosuppression
Jianqin Lu (2017)
Efficient drug-delivery using magnetic nanoparticles--biodistribution and therapeutic effects in tumour bearing rabbits.
R. Tietze (2013)
Biodegradable polymer iron oxide nanocomposites: the future of biocompatible magnetism.
R. A. Meyer (2015)
Immune checkpoint receptors in regulating immune reactivity in rheumatic disease
S. Ceeraz (2014)
Targeted delivery of gemcitabine to pancreatic adenocarcinoma using cetuximab as a targeting agent.
C. Patra (2008)
Advances and Challenges
V. Loerzel (2016)
The cellular and molecular basis of hyperthermia.
B. Hildebrandt (2002)
Cancer immunotherapy: harnessing the immune system to battle cancer.
Y. Yang (2015)
Targeting of drug‐loaded nanoparticles to tumor sites increases cell death and release of danger signals
Magdalena Alev (2018)
Profile of ipilimumab and its role in the treatment of metastatic melanoma
S. Patel (2011)
Magnetic Drug Targeting Reduces the Chemotherapeutic Burden on Circulating Leukocytes
C. Janko (2013)
Nanoparticle-mediated hyperthermia in cancer therapy.
D. Chatterjee (2011)
Cancer Nanomedicine: Lessons for Immuno-Oncology.
Shiladitya Sengupta (2017)
Inducing enhanced immunogenic cell death with nanocarrier-based drug delivery systems for pancreatic cancer therapy.
Xiao Zhao (2016)
risks, consequences, and new directions for its management
J Crawford (2004)
This paper is referenced by
Biocompatible superparamagnetic core-shell nanoparticles for potential use in hyperthermia-enabled drug release and as an enhanced contrast agent.
Yogita Patil-Sen (2020)
Active targeting co-delivery of therapeutic Sur siRNA and an antineoplastic drug via epidermal growth factor receptor-mediated magnetic nanoparticles for synergistic programmed cell death in glioblastoma stem cells
Xueqin Wang (2020)
Mitoxantrone-Loaded Nanoparticles for Magnetically Controlled Tumor Therapy–Induction of Tumor Cell Death, Release of Danger Signals and Activation of Immune Cells
Teresa Ratschker (2020)
New combination treatment from ROS-Induced sensitized radiotherapy with nanophototherapeutics to fully eradicate orthotopic breast cancer and inhibit metastasis.
Te-I Liu (2020)
In Vitro and In Vivo Antioxidant Activity of the New Magnetic-Cerium Oxide Nanoconjugates
Ioana-Andreea Turin-Moleavin (2019)
Superparamagnetic chitosan nanocomplexes for colorectal tumor-targeted delivery of irinotecan.
Danjun Wu (2020)
A New Pharmacokinetic Model Describing the Biodistribution of Intravenously and Intratumorally Administered Superparamagnetic Iron Oxide Nanoparticles (SPIONs) in a GL261 Xenograft Glioblastoma Model
Alexander P Klapproth (2020)
Iron Oxide/Salicylic Acid Nanoparticles as Potential Therapy for B16F10 Melanoma Transplanted on the Chick Chorioallantoic Membrane
M. C. Predoi (2020)
Biotechnological approach to induce human fibroblast apoptosis using superparamagnetic iron oxide nanoparticles.
Fausto Ferraz (2020)
SiO2-PVA-Fe(acac)3 Hybrid Based Superparamagnetic Nanocomposites for Nanomedicine: Morpho-textural Evaluation and In Vitro Cytotoxicity Assay
A. Putz (2020)
Investigation of Dextran-Coated Superparamagnetic Nanoparticles for Targeted Vinblastine Controlled Release, Delivery, Apoptosis Induction, and Gene Expression in Pancreatic Cancer Cells
S. Albukhaty (2020)
The yin and yang of imaging tumor associated macrophages with PET and MRI
S. Mukherjee (2019)
Tailoring Iron Oxide Nanoparticles for Efficient Cellular Internalization and Endosomal Escape
Laura Rueda-Gensini (2020)